Brief: Ocugen Announces Dosing Completion Of Subjects With Stargardt In Cohort 1 Of Phase 1/2 Clinical Trial
22/02/2024 21:34
Feb 22 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES DOSING COMPLETION OF SUBJECTS WITH
STARGARDT IN COHORT 1 OF PHASE 1/2 CLINICAL TRIAL EVALUATING THE
SAFETY AND EFFICACY OF OCU410ST
Source text for Eikon: ID:nGNX9TGsvt
Further company coverage: OCGN.O
(Reuters.Briefs@thomsonreuters.com)